Sanders Morris Harris LLC Acquires 557 Shares of AstraZeneca PLC (NASDAQ:AZN)

Sanders Morris Harris LLC increased its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 4.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,929 shares of the company’s stock after buying an additional 557 shares during the period. Sanders Morris Harris LLC’s holdings in AstraZeneca were worth $848,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. McClarren Financial Advisors Inc. boosted its holdings in shares of AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after acquiring an additional 247 shares during the period. Capital Performance Advisors LLP acquired a new position in AstraZeneca in the third quarter valued at about $28,000. Groupama Asset Managment raised its position in shares of AstraZeneca by 22.9% in the 3rd quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock valued at $42,000 after buying an additional 101,225 shares in the last quarter. Ashton Thomas Securities LLC bought a new position in AstraZeneca in the third quarter valued at approximately $45,000. Finally, Versant Capital Management Inc raised its holdings in shares of AstraZeneca by 2,618.5% during the 4th quarter. Versant Capital Management Inc now owns 734 shares of the company’s stock worth $48,000 after buying an additional 707 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

AZN has been the subject of a number of research analyst reports. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, AstraZeneca presently has an average rating of “Buy” and an average price target of $89.75.

AstraZeneca Trading Up 0.3 %

NASDAQ:AZN opened at $65.90 on Thursday. The stock has a market capitalization of $204.33 billion, a price-to-earnings ratio of 31.53, a PEG ratio of 1.05 and a beta of 0.46. The firm has a fifty day simple moving average of $65.98 and a two-hundred day simple moving average of $74.69. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. The firm had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.87 earnings per share. Analysts expect that AstraZeneca PLC will post 4.11 EPS for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.